Vallianou Natalia G, Tsilingiris Dimitrios, Karampela Irene, Liu Junli, Dalamaga Maria
First Department of Internal Medicine, Evangelismos General Hospital, 45-47 Ipsilantou Str, 10676, Athens, Greece.
First Department of Propaedeutic Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Laiko General Hospital, 17 St Thomas Street, 11527, Athens, Greece.
Metabol Open. 2022 Mar;13:100171. doi: 10.1016/j.metop.2022.100171. Epub 2022 Feb 10.
Reactivation of varicella-zoster virus (VZV) has been reported after the administration of different vaccine platforms against SARS-CoV-2, also among individuals without known immunosuppressive states. Herein, we describe for the first time a case of herpes zoster after mRNA vaccination against SARS-CoV-2 in a 53-year-old immunocompetent adult without any known comorbidities, who was previously vaccinated with a live attenuated zoster vaccine. The fact that the patient had no history of varicella and had been tested seronegative for VZV prior to immunization with the live attenuated zoster vaccine further contribute to the challenge of this unusual case. This advocates for a high level of vigilance on the part of clinicians regarding this rare complication among receivers of COVID-19 vaccines.
据报道,在接种针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的不同疫苗平台后,水痘带状疱疹病毒(VZV)会重新激活,在无已知免疫抑制状态的个体中也是如此。在此,我们首次描述了一例在接种针对SARS-CoV-2的mRNA疫苗后发生带状疱疹的病例,患者为一名53岁免疫功能正常的成年人,无任何已知合并症,此前曾接种过减毒活带状疱疹疫苗。患者无水痘病史,在接种减毒活带状疱疹疫苗之前VZV血清学检测呈阴性,这一事实进一步增加了这一罕见病例的复杂性。这提倡临床医生对新冠疫苗接种者中的这种罕见并发症保持高度警惕。